This HTML5 document contains 56 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00670/identifier/drugbank/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00670/identifier/chemspider/
n15http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00670/identifier/chebi/
n7http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00670/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00670/identifier/pharmgkb/
n3http://linked.opendata.cz/ontology/drugbank/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00670/identifier/kegg-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/drugbank/drug/DB00670/identifier/pubchem-compound/
n11http://linked.opendata.cz/ontology/sukl/drug/
n12http://linked.opendata.cz/resource/atc/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00670/identifier/pubchem-substance/

Statements

Subject Item
n2:DB00670
rdf:type
n3:Drug
n3:description
An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as cimetidine and ranitidine. It is generally well tolerated by patients. [PubChem]
n3:generalReferences
# Czepita D: [Fundamentals of modern treatment of myopia] Ann Acad Med Stetin. 2005;51(2):5-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16519089
n3:group
approved
n3:indication
For the treatment of peptic ulcer, gastric ulcer, and duodenal ulcer.
owl:sameAs
n7:DB00670 n15:DB00670
dcterms:title
Pirenzepine
adms:identifier
n9:4848 n10:46509029 n13:C07508 n14:PA10159 n16:DB00670 n17:8247 n18:4682 n19:Pirenzepine
n3:mechanismOfAction
Pirenzepine is a muscarinic receptor antagonist and binds to the muscarinic acetylcholine receptor. The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins.
n3:synonym
Pirenzepinum Pirenzépine 11-((4-Methyl-1-piperazinyl)acetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one Pirenzepina Pirenzepin
n3:foodInteraction
Take 30 minutes before breakfast and at bedtime.
n3:salt
n3:IUPAC-Name
n4:271B40AB-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B40B1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B40B0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B40AD-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B40AE-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B40AF-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B40A9-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B40A7-363D-11E5-9242-09173F13E4C5 n4:271B40AA-363D-11E5-9242-09173F13E4C5 n4:271B40C1-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B40A8-363D-11E5-9242-09173F13E4C5
n11:hasATCCode
n12:A02BX03
n3:H-Bond-Acceptor-Count
n4:271B40B7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B40B8-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B40B2-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B40B3-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B40B5-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B40B4-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B40B6-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:caco2-Permeability
n4:271B40C2-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
28797-61-7
n3:category
n3:Bioavailability
n4:271B40BD-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B40BF-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B40C0-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B40BC-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B40BB-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B40BE-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B40AC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B40B9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B40BA-363D-11E5-9242-09173F13E4C5